Alzamend Neuro (ALZN) Stock Chart & Stock Price History $3.17 +0.01 (+0.32%) Closing price 04:00 PM EasternExtended Trading$3.23 +0.06 (+2.02%) As of 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Alzamend Neuro Stock Price Performance The Alzamend Neuro (ALZN) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 90.56%, with a year-to-date return of -69.64%. In the past month, the stock has decreased 2.16%, reflecting recent market activity. As of the latest close, Alzamend Neuro traded at $3.16 with a market cap of $2.53 million and volume of 363,327 shares. Receive ALZN Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Alzamend Neuro and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+3.93%1 Month Performance-2.16%3 Month Performance-53.65%Year-To-Date Performance-69.64%1 Year Performance-90.56% ALZN Stock Chart for Tuesday, July, 15, 2025 ALZN Chart by TradingView Alzamend Neuro Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization07/14/2025$3.20$3.16-1.25%$3.28$3.09363,327 shs$2.53 million07/11/2025$3.05$3.20+4.92%$3.35$2.95448,487 shs$2.56 million07/10/2025$3.06$3.05-0.33%$3.13$3.00165,262 shs$2.44 million07/09/2025$2.95$3.06+3.73%$3.09$2.89178,098 shs$2.45 million07/08/2025$2.88$2.95+2.43%$2.96$2.8586,225 shs$2.36 million07/07/2025$2.97$2.88-2.87%$2.93$2.81127,726 shs$2.31 million07/04/2025$2.97$2.97$3.04$2.9089,378 shs$2.38 million07/03/2025$3.00$2.97-1.17%$3.04$2.9089,378 shs$2.37 million07/02/2025$2.92$3.00+2.74%$3.05$2.87393,042 shs$2.40 million07/01/2025$2.91$2.92+0.34%$2.92$2.81111,252 shs$2.34 million Get the Latest News and Ratings for ALZN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Alzamend Neuro and its competitors with MarketBeat's FREE daily newsletter. 06/30/2025$2.90$2.91+0.34%$2.97$2.84196,813 shs$2.33 million06/27/2025$2.92$2.90-0.68%$2.96$2.82131,052 shs$2.32 million06/26/2025$2.90$2.92+0.69%$2.95$2.75289,148 shs$2.34 million06/25/2025$2.93$2.90-1.02%$2.98$2.80231,041 shs$2.32 million06/24/2025$2.95$2.93-0.68%$2.98$2.79317,242 shs$2.34 million06/23/2025$3.04$2.95-2.96%$3.06$2.86253,368 shs$2.36 million06/20/2025$3.02$3.04+0.66%$3.06$2.93168,566 shs$2.44 million06/19/2025$3.02$3.02$3.07$2.94291,284 shs$2.42 million06/18/2025$2.97$3.02+1.68%$3.07$2.94291,284 shs$2.42 million06/17/2025$3.09$2.97-3.88%$3.06$2.90217,259 shs$2.38 million06/16/2025$3.24$3.09-4.63%$3.27$2.98426,983 shs$2.48 million Related Companies AEON Biopharma Stock Chart Dogwood Therapeutics Stock Chart GeoVax Labs Stock Chart Jade Biosciences Stock Chart Cellectar Biosciences Stock Chart Chromocell Therapeutics Stock Chart Kiora Pharmaceuticals Stock Chart Biomerica Stock Chart Turnstone Biologics Stock Chart Traws Pharma Stock Chart Receive ALZN Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Alzamend Neuro and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:ALZN) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alzamend Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
